◀ Back to ADCYAP1

ADCYAP1 — IL2

Text-mined interactions from Literome

Wang et al., Regul Pept 1999 : Previous reports indicate that VIP and the structurally related peptide PACAP , inhibit IL-2 and IL-10 production in antigen stimulated T lymphocytes ... The antagonists based on the neurotensin-VIP hybrid molecule did not affect the inhibitory effect of VIP/PACAP on IL-2 and IL-10 production, confirming that astrocytes and T lymphocytes express different receptors
Delgado et al., J Biol Chem 1999 : We showed previously that VIP and PACAP inhibit the production of macrophage derived tumor necrosis factor-alpha, interleukin (IL)-6 , nitric oxide, and IL-12
Wang et al., J Neuroimmunol 2000 : The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells
Zhang et al., Curr Eye Res 2005 : To examine pituitary adenylate cyclase activating polypeptide ( PACAP ) receptors ( PAC1, VPAC1, and VPAC2 ) mRNA and the effect of PACAP on interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) expression in human retinal pigment epithelial cell line ( ARPE-19 ) stimulated with interleukin-1beta (IL-1beta)
Mester et al., J Mol Neurosci 2011 : PACAP receptors have been identified on the retinal pigment epithelial cells and PACAP has been shown to inhibit interleukin secretion from pigment epithelial cells
Jiang et al., Ann N Y Acad Sci 1998 : These results indicate that both subsets of peripheral T lymphocytes express VIP1 and VIP2, but not PVR1 receptors, and that the inhibitory effect of VIP/PACAP on IL-2 and IL-10 production is mediated by both VIP1 and VIP2 receptors